Medicenna Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	2015 - 2019
Net Income	-26.9	-25.47	-10.05	-22.58	-17.29	-8.28	Upgrade
Depreciation & Amortization	0.04	0	0	0.04	0.04	0.01	Upgrade
Stock-Based Compensation	2.21	1.21	1.37	1.42	1.01	1.13	Upgrade
Other Operating Activities	8.79	7.25	-6.39	-0.62	0.25	2.52	Upgrade
Change in Accounts Receivable	0.42	1.68	1.23	-0.39	-1.61	0.14	Upgrade
Change in Accounts Payable	-0.89	-0.94	1.18	-1.45	2.29	-0.93	Upgrade
Operating Cash Flow	-16.34	-16.26	-12.66	-23.58	-15.31	-5.42	Upgrade
Capital Expenditures	-0.03	-	-	-	-	-	Upgrade
Investment in Securities	-	-	-	10.05	5.01	-15	Upgrade
Investing Cash Flow	-0.03	-	-	10.05	5.01	-15	Upgrade
Long-Term Debt Repaid	-	-	-	-0.04	-0.04	-0	Upgrade
Total Debt Repaid	-	-	-	-0.04	-0.04	-0	Upgrade
Net Debt Issued (Repaid)	-	-	-	-0.04	-0.04	-0	Upgrade
Issuance of Common Stock	23.81	-	24.76	3.92	18.3	40.75	Upgrade
Other Financing Activities	-0.3	-	-	-	-	-	Upgrade
Financing Cash Flow	23.51	-	24.76	3.88	18.26	40.75	Upgrade
Foreign Exchange Rate Adjustments	1.1	-0.35	0.96	-0.18	-0.28	-0	Upgrade
Net Cash Flow	8.24	-16.61	13.06	-9.84	7.68	20.33	Upgrade
Free Cash Flow	-16.37	-16.26	-12.66	-23.58	-15.31	-5.42	Upgrade
Free Cash Flow Per Share	-0.22	-0.23	-0.20	-0.43	-0.31	-0.17	Upgrade
Levered Free Cash Flow	-11.54	-2.78	-4.41	-15.14	-9.15	-2.05	Upgrade
Unlevered Free Cash Flow	-11.54	-2.78	-4.41	-15.14	-9.15	-2.05	Upgrade
Change in Net Working Capital	2.07	-7.68	-4.41	2.54	-0.68	-1.97	Upgrade

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.